SEARCH RESULTS FOR: "Tag: PSTI"
loading image
REFINE YOUR SEARCH:
ARTICLES/BLOGS
2018(1)
CATEGORIES
Analyst Update(1)

7/31/2018 2:15 PM
B. Riley/FBR initiated coverage on Pluristem Therapeutics Inc. (NASDAQ:PSTI) with a "buy" rating and $4.50 price target -- a roughly 266% premium to last night's close. The analyst in coverage cited ...
PEOPLE ALSO SEARCH FOR
 
Special Offers from Schaeffer's Trading Partners